Literature DB >> 14766374

Feline immunodeficiency virus: a concise review.

Luis Isamu Barros Kanzaki1, David J Looney.   

Abstract

Among non-primate vertebrates, feline immunodeficiency virus (FIV) infection in the cat may be the closest model of human immunodeficiency virus (HIV) infection and acquired immunodeficiency syndrome (AIDS). Clinical evolution and immunological and virological relationships between human HIV/AIDS and disease produced by FIV infection in cats are very close. These similarities should facilitate progress in the understanding of mechanisms of viral infection and immunopathology, and make this model potentially very valuable in evaluation of experimental therapeutic approaches to AIDS in man. Development of feline immunodeficiency virus vectors bearing therapeutic genes targeting different human diseases is a promising strategy for gene therapy, despite some recent studies which suggest that despite lack of evidence of infection of man by FIV, additional epidemiological surveillance may be indicated to determine if transmission can occur from this close companion to humans in some circumstances.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 14766374     DOI: 10.2741/1235

Source DB:  PubMed          Journal:  Front Biosci        ISSN: 1093-4715


  14 in total

1.  Treatment of chronically FIV-infected cats with suberoylanilide hydroxamic acid.

Authors:  Samantha J McDonnel; Molly L Liepnieks; Brian G Murphy
Journal:  Antiviral Res       Date:  2014-06-02       Impact factor: 5.970

2.  Major Histocompatibility Complex Class I (FLA-E*01801) Molecular Structure in Domestic Cats Demonstrates Species-Specific Characteristics in Presenting Viral Antigen Peptides.

Authors:  Ruiying Liang; Yaping Sun; Yanjie Liu; Junya Wang; Yanan Wu; Zibin Li; Lizhen Ma; Nan Zhang; Lijie Zhang; Xiaohui Wei; Zehui Qu; Nianzhi Zhang; Chun Xia
Journal:  J Virol       Date:  2018-02-26       Impact factor: 5.103

3.  Pharmacologic reactivation of latent feline immunodeficiency virus ex vivo in peripheral CD4+ T-lymphocytes.

Authors:  Samantha J McDonnel; Ellen E Sparger; Paul A Luciw; Brian G Murphy
Journal:  Virus Res       Date:  2012-10-13       Impact factor: 3.303

4.  Molecular characterization of feline immunodeficiency virus budding.

Authors:  Benjamin G Luttge; Miranda Shehu-Xhilaga; Dimiter G Demirov; Catherine S Adamson; Ferri Soheilian; Kunio Nagashima; Andrew G Stephen; Robert J Fisher; Eric O Freed
Journal:  J Virol       Date:  2007-12-19       Impact factor: 5.103

Review 5.  Restrictions to cross-species transmission of lentiviral infection gleaned from studies of FIV.

Authors:  Sue VandeWoude; Jennifer Troyer; Mary Poss
Journal:  Vet Immunol Immunopathol       Date:  2009-10-14       Impact factor: 2.046

6.  Transcriptional regulation of latent feline immunodeficiency virus in peripheral CD4+ T-lymphocytes.

Authors:  Samantha J McDonnel; Ellen E Sparger; Paul A Luciw; Brian G Murphy
Journal:  Viruses       Date:  2012-05-23       Impact factor: 5.048

Review 7.  HIV-1 and drug abuse comorbidity: Lessons learned from the animal models of NeuroHIV.

Authors:  Susmita Sil; Annadurai Thangaraj; Ernest T Chivero; Fang Niu; Muthukumar Kannan; Ke Liao; Peter S Silverstein; Palsamy Periyasamy; Shilpa Buch
Journal:  Neurosci Lett       Date:  2021-03-29       Impact factor: 3.197

Review 8.  Feline immunodeficiency virus latency.

Authors:  Samantha J McDonnel; Ellen E Sparger; Brian G Murphy
Journal:  Retrovirology       Date:  2013-07-06       Impact factor: 4.602

9.  Using dynamic stochastic modelling to estimate population risk factors in infectious disease: the example of FIV in 15 cat populations.

Authors:  David Fouchet; Guillaume Leblanc; Frank Sauvage; Micheline Guiserix; Hervé Poulet; Dominique Pontier
Journal:  PLoS One       Date:  2009-10-16       Impact factor: 3.240

10.  Could FIV zoonosis responsible of the breakdown of the pathocenosis which has reduced the European CCR5-Delta32 allele frequencies?

Authors:  Eric Faure
Journal:  Virol J       Date:  2008-10-16       Impact factor: 4.099

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.